Key clinical point: Tofacitinib improved dactylitis irrespective of the location and prevented its emergence in the majority of patients with psoriatic arthritis (PsA).
Major finding: In patients with Dactylitis Severity Scores (DSS) > 0, 10 mg tofacitinib twice daily vs placebo led to greater improvements in DSS for feet and other locations at month 1. By month 6, ≤15% of patients with DSS > 0 and <2% of patients with DSS = 0 reported the presence of dactylitis in all digits in the tofacitinib group.
Study details: Findings are from a post hoc analysis of two phase 3 trials including 710 patients with active PsA and inadequate response to conventional synthetic disease-modifying antirheumatic drugs (OPAL Broaden) or tumor necrosis factor inhibitors (OPAL Beyond) and who received 5/10 mg tofacitinib twice daily or placebo.
Disclosures: This study was sponsored by Pfizer Inc. Three authors declared being employees and shareholders of Pfizer. The other authors reported ties with several sources, including Pfizer.
Source: Orbai AM et al. Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: Post-hoc analysis of phase III studies. BMC Rheumatol. 2022;6(1):68 (Sep 1). Doi: 10.1186/s41927-022-00298-4